- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
EXACT Sciences Corporation (EXAS)
Track the EXACT Sciences share price today and view real-time EXAS share price data, including charts, technicals, and key financials. View the EXAS premarket stock price ahead of the market session or assess the after hours quote. Explore EXAS stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the EXACT Sciences Stock Price Today?
The EXACT Sciences stock price today is 104.91.
What Is the Stock Symbol for EXACT Sciences?
The stock symbol for EXACT Sciences is ""EXAS.""
What Stock Exchange Does EXACT Sciences Trade On?
EXACT Sciences is listed and trades on the NASDAQ stock exchange.
Is EXACT Sciences a Good Stock to Buy?
Determining whether EXACT Sciences or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EXAS quote. (ISIN: US30063P1057)
What Is the EXACT Sciences Stock Price Today?
The EXACT Sciences stock price today is 104.91.
What Is the Stock Symbol for EXACT Sciences?
The stock symbol for EXACT Sciences is ""EXAS.""
What Stock Exchange Does EXACT Sciences Trade On?
EXACT Sciences is listed and trades on the NASDAQ stock exchange.
Is EXACT Sciences a Good Stock to Buy?
Determining whether EXACT Sciences or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EXAS quote. (ISIN: US30063P1057)
104.91
+0.99(+0.95%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
104.90
104.98
52 wk Range
38.81
104.98
Showing EXACT Sciences historical data. For real-time data please try another search
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
104.90104.98
52 wk Range
38.81104.98
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EXAS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
105.87
Upside
+0.91%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Currently not supported.
- Form 8K EXACT Sciences Corporation For: 20 March
- Investing.com
- Form 8K EXACT Sciences Corporation For: 23 March
- Investing.com
- Abbott to close Exact Sciences acquisition on march 23
- Investing.com
Pro - Abbott completes acquisition of Exact Sciences
- Investing.com
Pro
- Form 8K EXACT Sciences Corporation For: 23 March
- Investing.com
- Abbott completes acquisition of Exact Sciences
- Investing.com
Pro - Exact Sciences stock hits 52-week high at $104.93
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. As of March 23, 2026, Exact Sciences Corporation operates as a subsidiary of Abbott Laboratories.
EXACT Sciences Corporation Earnings Call Summary for Q3/2025
- Exact Sciences reported Q3 2025 EPS of $0.24, surpassing forecasted loss of $0.03, with revenue of $851M exceeding expectations by 5.02% and growing 20% year-over-year.
- The company raised full-year revenue guidance to $3.22-3.235B and targets 15% compound annual growth rate from 2022-2027, with long-term goal of 20% adjusted EBITDA margins.
- Screening revenue rose 22% to $666M while precision oncology revenue increased 12% to $183M, driving a 37% rise in adjusted EBITDA to $135M.
- Free cash flow improved to $190M, up $77M from previous year, with stock price increasing 0.42% in aftermarket trading following the earnings announcement.
- CEO Kevin Conroy emphasized focus on cancer eradication through early detection, with expansion plans including international growth and investment in technologies like OncoDetect and MRD.
Last Updated: 04/11/2025, 10:28 am
Read Full TranscriptCompare EXAS to Peers and Sector
Metrics to compare | EXAS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEXASPeersSector | |
|---|---|---|---|---|
P/E Ratio | −96.3x | −2.6x | −0.5x | |
PEG Ratio | −1.20 | 0.26 | 0.00 | |
Price/Book | 8.3x | 2.6x | 2.6x | |
Price / LTM Sales | 6.2x | 2.8x | 3.1x | |
Upside (Analyst Target) | 0.1% | 701.8% | 55.9% | |
Fair Value Upside | Unlock | 8.5% | 7.4% | Unlock |
Analyst Ratings
1 Buy
20 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 105.87
(+0.91% Upside)
Earnings
Latest Release
13/02/2026
EPS / Forecast
-0.45 / -0.08
Revenue / Forecast
878.38M / 860.9M
People Also Watch
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.